Valneva SE announced that its senior management will present and hold meetings with institutional investors at upcoming healthcare conferences in the US and Europe. The company will focus on discussing the regulatory outlook for its Lyme disease vaccine candidate, developed with Pfizer, with decisions expected within 12 months. Valneva will also update on its R&D pipeline and potential future value if the Lyme vaccine is approved and commercialized. These presentations aim to highlight key value drivers and upcoming catalysts for investors.
As Valneva prepares to engage investors with updates on its Lyme disease vaccine and R&D pipeline, Pfizer shares are showing positive momentum. On Pluang, Pfizer (PFE) trades at USD 29.20, up 2.93% for the day as of Oct 14, 2026 22:52 WIB. Despite this rise, Pluang users are predominantly selling Pfizer shares, with 93% of order activity leaning that way, reflecting a cautious stance among retail investors.
Five large-cap dividend stocks—Altria, Verizon, Enbridge, Pfizer, and AT&T—offer yields around or above 5%, with four yielding over 6% due to recent price drops. Verizon and Altria stand out for their strong dividend growth and solid payout coverage,...
Johnson & Johnson's stock dropped 5% after reporting a 95.9% fall in net earnings caused by one-time charges including talc litigation costs, despite raising its full-year sales and adjusted earnings outlook. The company's Innovative Medicine divisio...
Pfizer reported $3.2 billion in Q2 sales from new and acquired products, an 18% increase year-over-year, nearing a $13 billion annual run-rate. The company has cut $7.2 billion in costs and beaten earnings estimates for 10 consecutive quarters. Howev...
